Specifically, combining oncolytic herpes simplex virus-1 (oHSV) and RTx, two modalities that converge on IGF1-Rmediated resistance, may enhance therapeutic efficacy and overcome tumor-intrinsic resistance. The gene discussed is IGF1; the disease is neoplasm.